Colin Meyer's most recent trade in Reata Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 2,144 Class A common stock done at an average price of $169.1 . Disclosure was reported to the exchange on Aug. 15, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 169.07 per share. | 15 Aug 2023 | 2,144 | 82,229 (0%) | 0% | 169.1 | 362,483 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 168.74 per share. | 15 Aug 2023 | 596 | 81,633 (0%) | 0% | 168.7 | 100,569 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2023 | 6,000 | 84,373 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 84.76 per share. | 15 May 2023 | 4,469 | 80,137 (0%) | 0% | 84.8 | 378,778 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 85.77 per share. | 15 May 2023 | 1,139 | 78,998 (0%) | 0% | 85.8 | 97,695 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 80.94 per share. | 15 May 2023 | 625 | 78,373 (0%) | 0% | 80.9 | 50,590 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 84.57 per share. | 07 Mar 2023 | 621 | 84,606 (0%) | 0% | 84.6 | 52,518 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 88,636 | 0 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 88,636 | 162,940 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | 02 Mar 2023 | 88,636 | 74,304 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | 02 Mar 2023 | 88,636 | 179,149 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 86.49 per share. | 02 Mar 2023 | 34,794 | 121,603 (0%) | 0% | 86.5 | 3,009,333 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 85.23 per share. | 02 Mar 2023 | 22,752 | 156,397 (0%) | 0% | 85.2 | 1,939,153 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 87.55 per share. | 02 Mar 2023 | 19,099 | 102,504 (0%) | 0% | 87.5 | 1,672,117 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 88.50 per share. | 02 Mar 2023 | 11,181 | 91,323 (0%) | 0% | 88.5 | 989,519 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 87.35 per share. | 02 Mar 2023 | 5,286 | 85,227 (0%) | 0% | 87.3 | 461,732 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Sale of securities on an exchange or to another person at price $ 90.58 per share. | 02 Mar 2023 | 810 | 90,513 (0%) | 0% | 90.6 | 73,370 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 30,000 | 30,000 | - | - | Employee Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 15,000 | 90,513 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 95,475 | 95,475 | - | - | Employee Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 23,513 | 75,513 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 35,000 | 52,000 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 24,000 | 24,000 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 18,605 | 95,031 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | 16 Nov 2020 | 18,605 | 90,605 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | 16 Nov 2020 | 18,605 | 59,779 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 18,605 | 78,384 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 170.48 per share. | 16 Nov 2020 | 12,174 | 78,431 (0%) | 0% | 170.5 | 2,075,397 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | 16 Nov 2020 | 6,395 | 78,395 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | 16 Nov 2020 | 6,395 | 59,779 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 6,395 | 66,174 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 6,395 | 88,636 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 171.38 per share. | 16 Nov 2020 | 3,824 | 74,607 (0%) | 0% | 171.4 | 655,367 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 164.44 per share. | 16 Nov 2020 | 2,450 | 75,945 (0%) | 0% | 164.4 | 402,888 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 172.61 per share. | 16 Nov 2020 | 2,207 | 72,400 (0%) | 0% | 172.6 | 380,943 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 166.14 per share. | 16 Nov 2020 | 1,930 | 72,200 (0%) | 0% | 166.1 | 320,643 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 165.25 per share. | 16 Nov 2020 | 1,815 | 74,130 (0%) | 0% | 165.2 | 299,922 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 170.59 per share. | 16 Nov 2020 | 200 | 72,000 (0%) | 0% | 170.6 | 34,118 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 174.98 per share. | 16 Nov 2020 | 200 | 72,100 (0%) | 0% | 175.0 | 34,996 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 175.00 per share. | 16 Nov 2020 | 100 | 72,000 (0%) | 0% | 175 | 17,500 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 173.75 per share. | 16 Nov 2020 | 100 | 72,300 (0%) | 0% | 173.8 | 17,375 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Colin Meyer | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 175.00 per share. | 09 Nov 2020 | 25,000 | 72,000 (0%) | 0% | 175 | 4,375,000 | Class A common stock |